At ILC, Bristol-Myers Squibb will present new Phase 2 data on BMS-986036, an investigational compound for non-alcoholic steatohepatitis, or NASH. NASH is a condition marked by excess fat in the liver, which can lead to complications including scarring, cirrhosis, liver failure, liver transplant, or cancer. Currently, the condition is severely underdiagnosed and there are no approved treatments for NASH, which is expected to become one of the leading causes of liver transplantation in the coming years. With a growing worldwide prevalence, the need for a better way to diagnose and treat NASH across the various stages of disease is very high. Read more about NASH.
We will also share an update on our research in hepatocellular carcinoma (HCC), the most common type of liver cancer, and the second most common cause of cancer-related deaths worldwide. More than 700,000 people around the world are diagnosed with HCC each year. The majority of these cases are caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, making HBV/HCV the most common risk factor for liver cancer. Additionally, evidence suggests that the progression of NASH can also cause the disease. HCC is often diagnosed in the advanced stage, where a significant unmet need exists. Read more about HCC.